Juvenescence lands $76m led by Abu Dhabi healthcare giant M42
Summary
The full close of the financing round is expected in the third quarter of this year, with the company reportedly aiming to raise more than $150 million in total.The new funding will enable Juvenescence to push forward its portfolio of therapeutics into further stages of clinical development and generate key data from ongoing trials. With a focus on addressing the biological mechanisms of aging to treat and prevent associated diseases, the companys development programs span cognition, cardio-metabolism, immunity and cellular repair, boasting a pipeline including a number of clinical and near-clinical stage candidates.Last month at Abu Dhabi Global Health Week, Juvenescence revealed it had entered into a strategic partnership with M42 to collaboratively develop AI-enabled therapeutics targeting aging and other life-threatening diseases. Along with todays funding news, more details on the strategic partnership between the two companies emerged, including a collaboration on a new AI-enabled drug development hub in Abu Dhabi, combining M42s infrastructure and expertise in clinical data, genomics and healthcare delivery with Juvenescences drug discovery capabilities to develop therapeutics designed to extend healthy lifespan.Juvenescence CEO Dr Richard Marshall said that the strategic partnership between the companies would accelerate the clinical development of Juvenescences pipeline, and hailed the opportunity to help build a leading life-sciences hub in Abu Dhabi and establish a pipeline of innovative therapeutics that will improve the lives of millions of patients.A steering committee made up of senior executives from both organizations will oversee the execution of the new development hub. The company already employs more than 20,000 people, and operates over 480 facilities across 26 countries, integrating genomics, biobanks, digital health data and AI technologies to deliver predictive, personalized healthcare. By uniting AI innovation with biotech expertise, were not only advancing the fight against age-related diseases but also building a global ecosystem that empowers prevention, precision and progress, delivering transformative therapies from Abu Dhabi to the world.